Aldeyra Therapeutics
ALDX
135 hedge funds and large institutions have $202M invested in Aldeyra Therapeutics in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 54 reducing their positions, and 11 closing their positions.
189% more call options, than puts
Call options by funds: $5.12M | Put options by funds: $1.77M
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
4% more funds holding
Funds holding: 130 → 135 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.56% less ownership
Funds ownership: 65.33% → 64.77% (-0.56%)
1% less capital invested
Capital invested by funds: $204M → $202M (-$2.41M)
30% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 54
Top Buyers
| 1 |
6CM
683 Capital Management
New York
|
+$3.65M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$2.66M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.3M |
| 4 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$1.15M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.14M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$5.33M |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$2.31M |
| 3 |
Morgan Stanley
New York
|
-$2.19M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.43M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$836K |
ALDX Hedge Fund Activity: Q4 2025 in Review
135 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2025, worth a combined $202M — down 1.2% from $204M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ALDX positions and 11 closed out — a net gain of 9 holders — while 38 added to existing stakes and 54 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $3.65M. The largest seller was Perceptive Advisors, cutting an estimated $5.33M.
- 135 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2025, up from 130 in Q3 2025.
- Funds reported $202M of Aldeyra Therapeutics stock for Q4 2025, down 1.2% quarter-over-quarter.
- 20 funds opened new Aldeyra Therapeutics positions in Q4 2025 and 11 closed out, a net change of +9 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2025 was 683 Capital Management, an estimated $3.65M added.
- The largest Aldeyra Therapeutics seller in Q4 2025 was Perceptive Advisors, an estimated $5.33M sold.
Based on aggregated 13F filings for Q4 2025.